GLP-1
Heidelberg Pharma AG published its financial results and annual report for fiscal year 2018 and its outlook for 2019.
Galapagos NV announces a share capital increase arising from warrant exercises.
The American College of Cardiology (ACC) annual meeting was held this weekend in New Orleans. Here’s a look at some of the top stories that came out of the meeting.
A turnover of €47.4 million, including €37.1 million related to the partnership signed with the Chinese company Tonghua Dongbao and €10.3 million following the judgment rendered in favor of Adocia in the first phase of the arbitration against Eli Lilly & Co
With Cowen & Company’s 39th Annual Health Care Conference going on in Boston this week, a lot of stories in the biopharma industry are coming out. Here are a few highlights.
LGC, Biosearch Technologies proudly introduces RapiDxFire™ Thermostable RT, a truly thermostable reverse transcriptase designed specifically to meet the needs of diagnostic kit developers.
Novo Nordisk announced the results from its SUSTAIN 9 Phase IIIb trial. The trial compared Novo’s Ozempic (semaglutide) with an SGLT-2 inhibitor or placebo in adults with type 2 diabetes.
In what is likely a preemptive move to avoid government action on insulin prices, Eli Lilly announced it will start selling an “authorized generic” version of Humalog 100 at about 50 percent off the list prices.
FINCH 2 Phase 3 trial with filgotinib in rheumatoid arthritis (RA) met all primary and secondary endpoints, with consistent tolerability
Adocia announced that four abstracts featuring its BioChaperone® technology have been accepted for presentation at the 12th International Conference on Advanced Technologies & Treatments for Diabetes being held February 20-23, 2019 in Berlin, Germany.
PRESS RELEASES